MicroRNAs as therapeutic targets and their potential applications in cancer therapy
Abstract
Introduction The results of cancer-associated miRNA research have yielded surprising insights into the pathogenesis of a range of different cancers. Many of the dysregulated miRNAs are involved in the regulation of genes that are essential for carcinogenesis. Areas covered This review discusses the latest discovery of miRNAs acting as oncogenes and tumor suppressor genes, as well as the potential applications of miRNA regulations in cancer therapy. Several translational studies have demonstrated the feasibility of targeting oncogenic miRNAs and restoring tumor-suppressive miRNAs for cancer therapy using in vivo model systems. Expert opinion miRNAs are extensive regulators of cancer progression. With increasing understanding of the miRNA target genes and the cellular behaviors influenced by them, modulating the miRNA activities may provide exciting opportunities for cancer therapy. Despite the hurdles incurred in acquiring effective systemic drug delivery systems, in vivo delivery of miRNAs for therapeutic purposes in preclinical animal models is rapidly developing. Accumulating evidences indicate that using miRNA expression alterations to influence molecular pathways has the potential of being translated into clinical applications.
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
miRNA-based therapeutics have an advantage over antibody therapy such as anti-Lingo1 because miRNAs are more stable.
“miRNA-based therapeutics have an advantage over antibody therapy such as anti-Lingo1 as miRNAs are more stable (Cho, 2012; Vicente et al., 2016).”
From miR-219 Cooperates with miR-338 in Myelination and Promotes Myelin Repair in the CNS (2017) · cites this paper as Cho, 2012
Cited by
Sorted by citations
miR-219 Cooperates with miR-338 in Myelination and Promotes Myelin Repair in the CNS
Wang, H., Moyano, A. L., Ma, Z., Deng, Y., Lin, Y., Zhao, C., Zhang, L., Jiang, M., He, X., Ma, Z., et al. (2017) · Developmental Cell · doi:10.1016/j.devcel.2017.03.001 · Cited by 174 · see citing works
Noguchi, S., Kumazaki, M., Yasui, Y., Mori, T., Yamada, N., & Akao, Y. (2014) · Journal of Investigative Dermatology · doi:10.1038/jid.2013.310 · Cited by 82 · see citing works
- Authors
- Cho, W. C.
- Venue
- Expert Opinion on Therapeutic Targets
- Publisher
- Informa Healthcare
- Published
- 2012-06-13
- Volume
- 16
- Issue
- 8
- Pages
- 747-759
- ISSN
- 1472-8222
- 1744-7631
- Cited by
- 59
- References
- 0
- Language
- en
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review